购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Lenvatinib

Rating icon 很棒
产品编号 T0520Cas号 417716-92-8
别名 仑伐替尼, E7080

Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。

Lenvatinib

Lenvatinib

Rating icon 很棒
纯度: 99.8000%
产品编号 T0520 别名 仑伐替尼, E7080Cas号 417716-92-8

Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。

规格价格库存数量
1 mg¥ 313现货
2 mg¥ 433现货
5 mg¥ 535现货
10 mg¥ 859现货
25 mg¥ 1,550现货
50 mg¥ 2,570现货
100 mg¥ 3,280现货
500 mg¥ 5,430现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Lenvatinib"的相关化合物库

选择批次:
纯度:99.8000%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
靶点活性
VEGFR3/FLT4:5.2 nM, PDGFRβ:39 nM, VEGFR1/FLT1:22 nM, FGFR1:46 nM, VEGFR2/KDR:4.0 nM
体外活性
方法:六种人肿瘤细胞 A375、DU145、DX3、KM12C、SK23 和 U2OS 用 Lenvatinib (1-100 μM) 处理 72 h,使用 MTT 检测细胞活力。
结果:大多数细胞系中,Lenvatinib 仅在高浓度下抑制增殖 (IC50 为 23.6-44.17 μM),而 KM12C 细胞系中的 IC50 为 9.54 μM。[1]
方法:人脐静脉内皮细胞 HUVECs 用 Lenvatinib (0.16-20 nM) 处理 1 h,随后用 SCF 或 VEGF (20 ng/mL) 刺激 5 min,使用 Western Blot 方法检测靶点蛋白表达水平。
结果:配体诱导的 KIT 和 KDR 的磷酸化均被 Lenvatinib 抑制。[2]
体内活性
方法:为检测体内抗肿瘤活性,将 Lenvatinib (30-100 mg/kg in 0.5% methylcellulose) 口服给药给携带人小细胞肺癌肿瘤 H146 的 BALB/c nude 小鼠,每天两次,持续二十一天。
结果:口服 Lenvatinib 以剂量依赖性方式抑制 H146 肿瘤的生长,并在 100 mg/kg 时引起肿瘤消退。[2]
方法:为检测体内抗肿瘤活性,将 Lenvatinib (100 mg/kg) 口服给药给携带人乳腺癌肿瘤 MDA-MB-231 的 nude 小鼠,每天一次,持续八周。
结果:Lenvatinib 在 MDA-MB-231 异种移植物模型中抑制向区域淋巴结和远处肺的转移。Lenvatinib 降低了淋巴结中 MDA-MB-231 肿瘤的已建立转移结节的血管生成和淋巴管生成。[3]
激酶实验
In vitro kinase assay [1]: Tyrosine kinase assays are performed by HTRF (KDR, VEGFR1, FGFR1, c-Met, EGFR) and ELISA (PDGFRβ), using the recombinant kinase domains of receptors. In both assays, 4 μL of serial dilutions of E7080 are mixed in a 96-well round plate with 10 μL of enzyme, 16 μL of poly (GT) solution (250 ng) and 10 μL of ATP solution (1 μM ATP) (final concentration of DMSO is 0.1%). In wells for blanks, no enzyme is added. In control wells no test article is added. The kinase reaction is initiated by adding ATP solution to each well. After 30-minute incubation at 30°C, the reaction is stopped by adding 0.5 M EDTA (10 μL/well) to the reaction mixture in each well. Dilution buffer adequate to each kinase assay is added to the reaction mixture. In the HTRF assay, 50 μL of the reaction mixture is transferred to a 96-well 1/2 area black EIA/RIA plate, HTRF solution (50 μL/well) is added to the reaction mixture, and then kinase activity is determined by measurement of fluorescence with a time-resolved fluorescence detector at an excitation wavelength of 337 nm and an emission wavelengths of 620 and 665 nm. In the ELISA, 50 μL of the reaction mixture is incubated in avidin coated 96-well polystyrene plates at room temperature for 30 minutes. After washing with wash buffer, PY20-HRP solution (70 μL/well) is added and the reaction mixture is incubated at room temperature for 30 minutes. After washing with wash buffer, TMB reagent (100 μL/well) is added to each well. After several minutes (10–30 minutes), 1 M H3PO4 (100 μL/well) is added to each well. Kinase activity is determined by measurement of absorbance at 450 nm with a microplate reader.
细胞实验
HUVECs (1,000 cells in each well in serum-free medium containing 2% fetal bovine serum) and L6 rat skeletal muscle myoblasts (5,000 cells in each well in serum-free DMEM) are dispensed in a 96-well plate and incubated overnight. E7080 and either VEGF (20 ng/mL) or FGF-2 (20 ng/mL) containing 2% fetal bovine serum and PDGFβ (40 ng/mL) are added to each well. Cells are incubated for 3 days and then the ratios of surviving cells are measured by WST-1 reagent. For proliferation assay, samples are duplicated and three separate experiments are done. (Only for Reference)
别名仑伐替尼, E7080
化学信息
分子量426.85
分子式C21H19ClN4O4
CAS No.417716-92-8
SmilesO(C=1C2=C(C=C(OC)C(C(N)=O)=C2)N=CC1)C3=CC(Cl)=C(NC(NC4CC4)=O)C=C3
密度1.46 g/cm3
储存&溶解度
存储store at low temperature | Powder: -20°C for 3 years | Shipping with blue ice.
溶解度信息
DMSO: 15 mg/mL (35.14 mM), Sonication is recommended.(The compound is unstable in solution, please use soon.)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.9 mg/mL (4.45 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
溶液配制表
1mg5mg10mg50mg
1 mM2.3427 mL11.7137 mL23.4274 mL117.1372 mL
1mg5mg10mg50mg
5 mM0.4685 mL2.3427 mL4.6855 mL23.4274 mL
10 mM0.2343 mL1.1714 mL2.3427 mL11.7137 mL
20 mM0.1171 mL0.5857 mL1.1714 mL5.8569 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Lenvatinib | purchase Lenvatinib | Lenvatinib cost | order Lenvatinib | Lenvatinib chemical structure | Lenvatinib in vivo | Lenvatinib in vitro | Lenvatinib formula | Lenvatinib molecular weight